Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Semuloparin. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Semuloparin. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Semuloparin. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Semuloparin is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Semuloparin. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Semuloparin. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Obinutuzumab. |
| Rivaroxaban | Semuloparin may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Semuloparin. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Semuloparin. |
| Urokinase | Urokinase may increase the anticoagulant activities of Semuloparin. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Semuloparin. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Semuloparin. |
| Valsartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Valsartan. |
| Olmesartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Olmesartan. |
| Losartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Losartan. |
| Candesartan cilexetil | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Candesartan cilexetil. |
| Eprosartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Eprosartan. |
| Telmisartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Telmisartan. |
| Irbesartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Irbesartan. |
| Forasartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Forasartan. |
| Saprisartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Saprisartan. |
| Tasosartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Tasosartan. |
| Saralasin | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Saralasin. |
| Azilsartan medoxomil | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Azilsartan medoxomil. |
| Fimasartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Fimasartan. |
| Candesartan | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Candesartan. |
| Ramipril | The risk or severity of hyperkalemia can be increased when Ramipril is combined with Semuloparin. |
| Fosinopril | The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Semuloparin. |
| Trandolapril | The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Semuloparin. |
| Benazepril | The risk or severity of hyperkalemia can be increased when Benazepril is combined with Semuloparin. |
| Enalapril | The risk or severity of hyperkalemia can be increased when Enalapril is combined with Semuloparin. |
| Moexipril | The risk or severity of hyperkalemia can be increased when Moexipril is combined with Semuloparin. |
| Lisinopril | The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Semuloparin. |
| Perindopril | The risk or severity of hyperkalemia can be increased when Perindopril is combined with Semuloparin. |
| Quinapril | The risk or severity of hyperkalemia can be increased when Quinapril is combined with Semuloparin. |
| Omapatrilat | The risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Semuloparin. |
| Rescinnamine | The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Semuloparin. |
| Captopril | The risk or severity of hyperkalemia can be increased when Captopril is combined with Semuloparin. |
| Cilazapril | The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Semuloparin. |
| Spirapril | The risk or severity of hyperkalemia can be increased when Spirapril is combined with Semuloparin. |
| Temocapril | The risk or severity of hyperkalemia can be increased when Temocapril is combined with Semuloparin. |
| Enalaprilat | The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Semuloparin. |
| Imidapril | The risk or severity of hyperkalemia can be increased when Imidapril is combined with Semuloparin. |
| Zofenopril | The risk or severity of hyperkalemia can be increased when Zofenopril is combined with Semuloparin. |
| Delapril | The risk or severity of hyperkalemia can be increased when Delapril is combined with Semuloparin. |
| Benazeprilat | The risk or severity of hyperkalemia can be increased when Benazeprilat is combined with Semuloparin. |
| Fosinoprilat | The risk or severity of hyperkalemia can be increased when Fosinoprilat is combined with Semuloparin. |
| Ramiprilat | The risk or severity of hyperkalemia can be increased when Ramiprilat is combined with Semuloparin. |
| Trandolaprilat | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Semuloparin. |
| Moexiprilat | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Semuloparin. |
| Perindoprilat | The risk or severity of hyperkalemia can be increased when Perindoprilat is combined with Semuloparin. |
| Quinaprilat | The risk or severity of hyperkalemia can be increased when Quinaprilat is combined with Semuloparin. |
| Cilazaprilat | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Semuloparin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Semuloparin. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Semuloparin. |
| Quinine | The therapeutic efficacy of Semuloparin can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Semuloparin can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Semuloparin. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Semuloparin. |
| Corticorelin ovine triflutate | The risk or severity of hypotension and sinus node depression can be increased when Semuloparin is combined with Corticorelin ovine triflutate. |
| Oritavancin | The therapeutic efficacy of Semuloparin can be decreased when used in combination with Oritavancin. |
| Streptokinase | Streptokinase may increase the anticoagulant activities of Semuloparin. |
| Telavancin | The therapeutic efficacy of Semuloparin can be decreased when used in combination with Telavancin. |
| Palifermin | The serum concentration of Palifermin can be increased when it is combined with Semuloparin. |
| Pentoxifylline | The therapeutic efficacy of Semuloparin can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Semuloparin. |
| Levocarnitine | The therapeutic efficacy of Semuloparin can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Semuloparin. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Semuloparin. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Semuloparin. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Semuloparin. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Semuloparin. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Semuloparin. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Semuloparin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Semuloparin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Semuloparin. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Semuloparin. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Semuloparin. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Semuloparin. |
| Equol | Equol may decrease the anticoagulant activities of Semuloparin. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Semuloparin. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Semuloparin. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Semuloparin. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Semuloparin. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Semuloparin. |